221 related articles for article (PubMed ID: 2155504)
1. Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472----U.
Svitkin YV; Cammack N; Minor PD; Almond JW
Virology; 1990 Mar; 175(1):103-9. PubMed ID: 2155504
[TBL] [Abstract][Full Text] [Related]
2. Reversion to neurovirulence of the live-attenuated Sabin type 3 oral poliovirus vaccine.
Cann AJ; Stanway G; Hughes PJ; Minor PD; Evans DM; Schild GC; Almond JW
Nucleic Acids Res; 1984 Oct; 12(20):7787-92. PubMed ID: 6093054
[TBL] [Abstract][Full Text] [Related]
3. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine.
Westrop GD; Wareham KA; Evans DM; Dunn G; Minor PD; Magrath DI; Taffs F; Marsden S; Skinner MA; Schild GC
J Virol; 1989 Mar; 63(3):1338-44. PubMed ID: 2536836
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the complete nucleotide sequences of the genomes of the neurovirulent poliovirus P3/Leon/37 and its attenuated Sabin vaccine derivative P3/Leon 12a1b.
Stanway G; Hughes PJ; Mountford RC; Reeve P; Minor PD; Schild GC; Almond JW
Proc Natl Acad Sci U S A; 1984 Mar; 81(5):1539-43. PubMed ID: 6324200
[TBL] [Abstract][Full Text] [Related]
5. Towards development of an in vitro translation test for poliovirus neurovirulence.
Svitkin YV; Alpatova GA; Lipskaya GA; Maslova SV; Agol VI; Kew O; Meerovitch K; Sonenberg N
Dev Biol Stand; 1993; 78():27-32. PubMed ID: 8388829
[TBL] [Abstract][Full Text] [Related]
6. Studies on the attenuation of the Sabin type 3 oral polio vaccine.
Almond JW; Westrop GD; Evans DM; Dunn G; Minor PD; Magrath D; Schild GC
J Virol Methods; 1987 Aug; 17(1-2):183-9. PubMed ID: 2822753
[TBL] [Abstract][Full Text] [Related]
7. Role of mutations G-480 and C-6203 in the attenuation phenotype of Sabin type 1 poliovirus.
McGoldrick A; Macadam AJ; Dunn G; Rowe A; Burlison J; Minor PD; Meredith J; Evans DJ; Almond JW
J Virol; 1995 Dec; 69(12):7601-5. PubMed ID: 7494267
[TBL] [Abstract][Full Text] [Related]
8. Correlation of mutations and recombination with growth kinetics of poliovirus vaccine strains.
Pliaka V; Kyriakopoulou Z; Tsakogiannis D; Ruether IG; Gartzonika C; Levidiotou-Stefanou S; Krikelis A; Markoulatos P
Eur J Clin Microbiol Infect Dis; 2010 Dec; 29(12):1513-23. PubMed ID: 20820837
[TBL] [Abstract][Full Text] [Related]
9. Construction and properties of intertypic poliovirus recombinants: first approximation mapping of the major determinants of neurovirulence.
Agol VI; Grachev VP; Drozdov SG; Kolesnikova MS; Kozlov VG; Ralph NM; Romanova LI; Tolskaya EA; Tyufanov AV; Viktorova EG
Virology; 1984 Jul; 136(1):41-55. PubMed ID: 6330995
[TBL] [Abstract][Full Text] [Related]
10. Determinants in the 5' noncoding region of poliovirus Sabin 1 RNA that influence the attenuation phenotype.
Kawamura N; Kohara M; Abe S; Komatsu T; Tago K; Arita M; Nomoto A
J Virol; 1989 Mar; 63(3):1302-9. PubMed ID: 2536835
[TBL] [Abstract][Full Text] [Related]
11. Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine.
Pollard SR; Dunn G; Cammack N; Minor PD; Almond JW
J Virol; 1989 Nov; 63(11):4949-51. PubMed ID: 2552175
[TBL] [Abstract][Full Text] [Related]
12. Increased neurovirulence associated with a single nucleotide change in a noncoding region of the Sabin type 3 poliovaccine genome.
Evans DM; Dunn G; Minor PD; Schild GC; Cann AJ; Stanway G; Almond JW; Currey K; Maizel JV
Nature; 1985 Apr 11-17; 314(6011):548-50. PubMed ID: 2986004
[TBL] [Abstract][Full Text] [Related]
13. Mutations in Sabin 2 strain of poliovirus and stability of attenuation phenotype.
Rezapkin GV; Fan L; Asher DM; Fibi MR; Dragunsky EM; Chumakov KM
Virology; 1999 May; 258(1):152-60. PubMed ID: 10329577
[TBL] [Abstract][Full Text] [Related]
14. Evolution of the Sabin type 1 poliovirus in humans: characterization of strains isolated from patients with vaccine-associated paralytic poliomyelitis.
Georgescu MM; Balanant J; Macadam A; Otelea D; Combiescu M; Combiescu AA; Crainic R; Delpeyroux F
J Virol; 1997 Oct; 71(10):7758-68. PubMed ID: 9311861
[TBL] [Abstract][Full Text] [Related]
15. Reevaluation of nucleotide sequences of wild-type and attenuated polioviruses of type 3.
Rezapkin GV; Douthitt M; Dragunsky E; Chumakov KM
Virus Res; 1999 Dec; 65(2):111-9. PubMed ID: 10581384
[TBL] [Abstract][Full Text] [Related]
16. Attenuation stem-loop lesions in the 5' noncoding region of poliovirus RNA: neuronal cell-specific translation defects.
Haller AA; Stewart SR; Semler BL
J Virol; 1996 Mar; 70(3):1467-74. PubMed ID: 8627664
[TBL] [Abstract][Full Text] [Related]
17. Differences in replication of attenuated and neurovirulent polioviruses in human neuroblastoma cell line SH-SY5Y.
La Monica N; Racaniello VR
J Virol; 1989 May; 63(5):2357-60. PubMed ID: 2539524
[TBL] [Abstract][Full Text] [Related]
18. Mapping of mutations associated with neurovirulence in monkeys infected with Sabin 1 poliovirus revertants selected at high temperature.
Christodoulou C; Colbere-Garapin F; Macadam A; Taffs LF; Marsden S; Minor P; Horaud F
J Virol; 1990 Oct; 64(10):4922-9. PubMed ID: 2168976
[TBL] [Abstract][Full Text] [Related]
19. Covariance of lowered capacity to induce interferon in human leukocytes and temperature sensitivity of type 3 poliovirus.
Hovi T; Pitkäranta A; Macadam A; Minor P; Almond J
J Interferon Res; 1991 Apr; 11(2):105-10. PubMed ID: 1714485
[TBL] [Abstract][Full Text] [Related]
20. Oral poliovirus vaccine in the United States: molecular characterization of Sabin type 3 after replication in the gut of vaccinees.
Tatem JM; Weeks-Levy C; Mento SJ; DiMichele SJ; Georgiu A; Waterfield WF; Sheip B; Costalas C; Davies T; Ritchey MB
J Med Virol; 1991 Oct; 35(2):101-9. PubMed ID: 1662701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
